University of Tübingen
Germany to Test Genomics-Based Precision Medicine for Cancer, Rare Disease in National Pilot Project
Premium
With reimbursement from public health insurance, the "model project" will run for at least five years and examine the utility of genomic sequencing for advanced cancer and rare disease patients.
German Medical Center to Report Polygenic Risk Scores as Part of Clinical Whole-Genome Testing
Premium
Under the Ge-Med project, University Hospital Tübingen will offer diagnostic whole-genome sequencing for all genetic indications and will include PRS in its reporting.
European Rare Disease Research Consortium Plans to Diagnose Patients With 'Unsolvable' Disorders
Premium
Funded with €15.4 million from the EU's Horizon 2020 program, the researchers plan to reanalyze almost 20,000 patient exomes and conduct additional tests on selected subgroups.